Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | POLA1 | P09884 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 5/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28252087 | 0.91 | ADORA2A (0.47) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL11133896 | 0.84 | ADORA2A (0.47) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7680703 | 0.76 | XDH (0.60) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL28004982 | 0.73 | XDH (0.53) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL28080849 | 0.73 | ABL1 (0.41) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL28004933 | 0.72 | XDH (0.46) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1898184 | 0.72 | GDA (0.48) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL9706231 | 0.72 | PARP1 (0.54) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL28817761 | 0.72 | ADORA3 (0.49) | PDE4APDE4BPDE4CPDE4DADORA3 | |
| SCHEMBL28194636 | 0.71 | GDA (0.44) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002085904-A1 | SNYTHESIS AND METHODS OF USE OF PURINE ANALOGUES AND DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | NEO THERAPEUTICS, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | SLC29A1, ATIC, PNP | PDE4A 236/4885ADORA2A 4/4885PDE4B 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.